TargeGen Initiates Multi-Center Phase II Clinical Trial Of TG100801

TargeGen announced that it has initiated a multicenter Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD).

Currently approved treatments for AMD require repeated injection into the eye and act primarily by reducing vascular endothelial growth factor (VEGF)-mediated retinal leakage, TargeGen said.

TG100801 is administered non-invasively as an eye drop and is designed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, edema and angiogenesis that are the pathological hallmarks of AMD and other back-of-the-eye diseases, including diabetic macular edema and proliferative diabetic retinopathy, the company added.